Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sonnet BioTherapeutics Holdings, Inc. SONN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Sonnet BioTherapeutics Holdings, Inc. (SONN) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.

SONN Analyst Ratings

Buy
4
Ratings
4 Buy
Based on 4 analysts giving stock ratings to Sonnet BioTherapeutics Holdings, Inc. in the past 3 months
Rating breakdown
Buy
4 100%
100%
Buy
4 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 YS
YS
YS Biopharma Co., Ltd.
$1.02
+9.68%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 KRBP
KRBP
Kiromic BioPharma, Inc.
$0.08
-2.33%
 NAVB
NAVB
Navidea Biopharmaceuticals, Inc.
$0.00
0.00%
 EFTR
EFTR
eFFECTOR Therapeutics, Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message